Abstract
Objective We describe magnetic resonance spectroscopy (MRS) changes in comatose patients undergoing targeted temperature management (TTM) after cardiac arrest, and their relationships to relevant clinical, MRI, and EEG variables.
Methods A prospective cohort of 50 patients was studied. The primary outcome was coma recovery to follow commands. Comparison of MRS measures in the posterior cingulate gyrus, parietal white matter, basal ganglia, and brainstem were also made to 25 normative control subjects.
Results Fourteen of 50 achieved coma recovery. Compared to patients who recovered, there was a significant decrease in total N-acetyl-aspartate (NAA/Cr) and glutamate; and an increase in lactate (Lac/Cr) and glutamine in patients who did not recover, with changes most prominent in the posterior cingulate gyrus. Patients who recovered had a decrease in NAA/Cr as compared to control subjects. Coma recovery was seen in patients with a moderate decrease in NAA/Cr, but the appearance of lactate resulted in a poor outcome. NAA/Cr had a linear relationship with MRI cortical apparent diffusion coefficient (ADC); lactate level exponentially increased with decreasing ADC. EEG suppression/burst suppression was universally associated with lactate elevation.
Conclusions NAA and lactate changes are associated with clinical/MRI/EEG changes consistent with anoxic brain injury and are most prominent in the posterior cingulate gyrus. NAA/Cr decrease observed in patients with good outcomes suggests mild anoxic injury in patients asymptomatic at hospital discharge. The appearance of cortical lactate represents a deterioration of aerobic energy metabolism and is associated with EEG background suppression, synaptic transmission failure, and severe, potentially irreversible anoxic injury.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
None
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Institutional Review Board of Mass General Brigham which oversees all human-subject research conducted by a Mass General Brigham-affiliated investigator approved this study, and consent was obtained for each patient by the legally authorized representative unless MRS was performed as part of clinical care.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Supplemental: Response to Reviewers Updated STROBE Checklist
Statistical Analysis performed by: Camden Bay, PhD
Study Funding: The authors report no targeted funding
Disclosures: Jong Woo Lee has performed contract work for Teladoc and Bioserenity, he was the site PI for Engage Therapeutics, he has received research funding from the NINDS, he is the co-founder of Soterya, Inc;
Lasya Sreepada reports no disclosures relevant to the manuscript;
Matthew Bevers is supported by grants from the American Academy of Neurology and National Institute of Neurologic Disorders and Stroke, he reports research funding and personal fees from Biogen, outside the scope of the current work;
Karen Li reports no disclosures relevant to the manuscript;
Benjamin Scirica reports Institutional research grant to Brigham and Women’s Hospital from AstraZeneca, Eisai, Novartis, and Merck, consulting fees from AbbVie, Allergan, AstraZeneca, Boehringer Ingelheim, Covance, Eisai, Elsevier Practice Update Cardiology, GlaxoSmithKline, Lexicon, Medtronic, Merck, NovoNordisk, Sanofi, and equity in Health [at] Scale, is a member of the TIMI Study Group which has received institutional research grant support through Brigham and Women’s Hospital from: Abbott, Amgen, Aralez, AstraZeneca, Bayer HealthCare Pharmaceuticals, Inc., BRAHMS, Daiichi-Sankyo, Eisai, GlaxoSmithKline, Intarcia, Janssen, MedImmune, Merck, Novartis, Pfizer, Poxel, Quark Pharmaceuticals, Roche, Takeda, The Medicines Company, Zora Biosciences;
Danuzia Silva reports no disclosures relevant to the manuscript;
Galen V. Henderson reports no disclosures relevant to the manuscript;
Camden Bay reports no disclosures relevant to the manuscript; Alexander Lin is a consultant for Agios Pharmaceuticals, Biomarin Pharmaceuticals, Moncton MRI and is cofounder of BrainSpec. He receives research funding from NINDS, NIA, Department of Defense, and the Alzheimers Association.
Data Availability
Data will be shared at the request of other investigators for purposes of replicating procedures and results.
